Biota Holdings (BTA) is an Australian based, anti-infective drug development company.

The group specialises in the discovery and development of pharmaceuticals, focusing on research for the treatment of viral respiratory diseases, particularly influenza (flu).

It was one of the shares to sell from mid-February following a disappointing half year result.

However, BTA surged on Friday after it was awarded a US$231 million contract for the advanced development of its laninamivir drug.

Laninamivir is an influenza antiviral, which offers the ability to treat an influenza infection.

The contract will be fully funded over five years and is dependent on Biota Holdings achieving key milestones throughout the period.

BTA rocketed over 35% following the announcement, making it the best performer in the Australian share market.

For FREE Best Shares and Biota Holdings advice, click here.

   Written by: admin   Other posts from: admin

Biota (BTA) is an Australian based, anti-infective drug development company.

The group specialises in the discovery and development of pharmaceuticals, focusing on research for the treatment of viral respiratory diseases, particularly influenza (flu).

Recently, BTA announced that Japan-based Daiichi Sankyo has received approval to manufacture and market its product, Inavir.

Inavir is an anti-viral drugs designed to treat or prevent influenza infections.

Under the agreement, BTA will receive a royalty on all sales in Japan, and both companies are now in talks to market Inavir to the rest of the world.

BTA will be one of the top shares to watch in coming months, as the market waits to see whether the group can successfully launch Inavir on a global scale.

BTA shares rocketed 17% on day of the announcement, making it one of the best performers on the Australian share market.

   Written by: admin   Other posts from: admin